Payment overview · 2025
General Payments
$637.30
22 reported records · 12 companies
Healthcare provider profile · identity verified
Brandi E Guthrey, MD
Allopathic & Osteopathic Physicians|Family Medicine · FORT SMITH, AR · NPI 1073712212
Verified facts
What the public records show
CMS Open Payments records show Brandi E Guthrey, MD received $637.30 in general payments during 2025 across 22 reported records.
AstraZeneca Pharmaceuticals LP accounted for 36.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $232.17 | 36.4% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $143.57 | 22.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $49.70 | 7.8% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $37.15 | 5.8% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $30.93 | 4.8% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $30.62 | 4.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $26.33 | 4.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $24.91 | 3.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.91 | 3.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.73 | 2.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.64 | 2.3% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.64 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $637.30 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $177.49 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $143.57 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $85.84 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $37.15 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $34.60 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $31.16 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $30.93 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $30.62 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $26.33 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.91 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.10 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 151 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
45 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
51 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
151 | 31 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 516 | 148 |
| Amlodipine Besylate | Amlodipine Besylate | 432 | 131 |
| Omeprazole | Omeprazole | 386 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 362 | 82 |
| Lisinopril | Lisinopril | 307 | 88 |
| Potassium Chloride | Potassium Chloride | 297 | 89 |
| Gabapentin | Gabapentin | 249 | 70 |
| Losartan Potassium | Losartan Potassium | 234 | 70 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 229 | 57 |
| Tramadol Hcl | Tramadol Hcl | 216 | 41 |
| Furosemide | Furosemide | 214 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 191 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 180 | 57 |
| Trazodone Hcl | Trazodone Hcl | 173 | 51 |
| Tizanidine Hcl | Tizanidine Hcl | 156 | 34 |
| Ozempic | Semaglutide | 151 | 31 |
| Carvedilol | Carvedilol | 147 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 143 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 142 | 47 |
| Jardiance | Empagliflozin | 136 | 38 |
| Alprazolam | Alprazolam | 133 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 130 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 129 | 35 |
| Meloxicam | Meloxicam | 124 | 46 |
| Eliquis | Apixaban | 119 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 117 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 102 | 35 |
| Buspirone Hcl | Buspirone Hcl | 101 | 29 |
| Clonazepam | Clonazepam | 99 | 17 |
| Metformin Hcl | Metformin Hcl | 98 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 96 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 39 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | 28 |
| Ondansetron Odt | Ondansetron | 90 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 86 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 86 | 28 |
| Sertraline Hcl | Sertraline Hcl | 76 | 22 |
| Simvastatin | Simvastatin | 76 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 75 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 73 | 18 |
| Alendronate Sodium | Alendronate Sodium | 72 | 21 |
| Metformin Hcl Er | Metformin Hcl | 69 | 22 |
| Prednisone | Prednisone | 69 | 39 |
| Tresiba Flextouch U-100 | Insulin Degludec | 69 | suppressed |
| Mounjaro | Tirzepatide | 68 | 11 |
| Allopurinol | Allopurinol | 67 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 65 | 18 |
| Pregabalin | Pregabalin | 64 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 62 | 15 |
| Estradiol | Estradiol | 61 | 16 |
| Ranolazine Er | Ranolazine | 60 | 18 |
| Glimepiride | Glimepiride | 58 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 17 |
| Lorazepam | Lorazepam | 57 | suppressed |
| Azithromycin | Azithromycin | 55 | 48 |
| Mirtazapine | Mirtazapine | 54 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 54 | 33 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | suppressed |
| Synthroid | Levothyroxine Sodium | 51 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 49 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 46 | 17 |
| Valacyclovir | Valacyclovir Hcl | 46 | 16 |
| Linzess | Linaclotide | 45 | 13 |
| Clonidine Hcl | Clonidine Hcl | 44 | 13 |
| Nitroglycerin | Nitroglycerin | 44 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 16 |
| Montelukast Sodium | Montelukast Sodium | 43 | 14 |
| Nystatin | Nystatin | 43 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | 12 |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Fenofibrate | Fenofibrate | 41 | suppressed |
| Bupropion Xl | Bupropion Hcl | 40 | 12 |
| Ezetimibe | Ezetimibe | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 38 | 30 |
| Spironolactone | Spironolactone | 38 | 13 |
| Aripiprazole | Aripiprazole | 37 | suppressed |
| Atenolol | Atenolol | 37 | suppressed |
| Klor-Con M20 | Potassium Chloride | 37 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 37 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 37 | 13 |
| Fluconazole | Fluconazole | 36 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 33 |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 29 |
| Methimazole | Methimazole | 34 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 34 | suppressed |
| Sucralfate | Sucralfate | 34 | 15 |
| Colestipol Hcl | Colestipol Hcl | 33 | 13 |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Cefdinir | Cefdinir | 32 | 27 |
| Clobetasol Propionate | Clobetasol Propionate | 32 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 30 | suppressed |
| Torsemide | Torsemide | 29 | suppressed |
| Celecoxib | Celecoxib | 27 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Metolazone | Metolazone | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Colchicine | Colchicine | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 19 |
| Mupirocin | Mupirocin | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 15 |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 13 |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 14 |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 13 | 13 |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Ubrelvy | Ubrogepant | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Leflunomide | Leflunomide | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $637.30 · 22 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, Ozempic, REXULTI, Rybelsus, Symbravo, The Cologuard Plus Collection Kit, VRAYLAR, XIFAXAN, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error